A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics
Open Access
- 9 May 2013
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 94 (3) , 394-399
Abstract
Metoprolol, a commonly prescribed β‐blocker, is primarily metabolized by cytochrome P450 2D6 (CYP2D6), an enzyme with substantial genetic heterogeneity. Several smaller studies have shown that metopr...Keywords
This publication has 29 references indexed in Scilit:
- Genetic Variation, β-blockers, and Perioperative Myocardial InfarctionAnesthesiology, 2011
- From Pharmacogenomic Knowledge Acquisition to Clinical Applications: The PharmGKB as a Clinical Pharmacogenomic Biomarker ResourceBiomarkers in Medicine, 2011
- Toward Optimal Treatment in Women: The Effect of Sex on Metoprolol‐Diphenhydramine InteractionThe Journal of Clinical Pharmacology, 2010
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Influence ofCYP2D6*10on the pharmacokinetics of metoprolol in healthy Korean volunteersJournal of Clinical Pharmacy and Therapeutics, 2008
- Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemiaBritish Journal of Clinical Pharmacology, 2008
- Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical PracticePharmacological Reviews, 2006
- Modulation of Metoprolol Pharmacokinetics and Hemodynamics by Diphenhydramine Coadministration during Exercise Testing in Healthy Premenopausal WomenThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Influence of hydroxychloroquine on the bioavailability of oral metoprololBritish Journal of Clinical Pharmacology, 2000
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseNew England Journal of Medicine, 1982